LKT Labs

Biochemicals for Life Science Research

Saracatinib

Saracatinib

Product ID S0168
Cas No. 379231-04-6
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $45.00 In stock
5 mg $68.00 In stock
25 mg $225.00 In stock
Bulk Quote

Quicklinks

Description

Saracatinib is an inhibitor of Src and Abl family kinases that is used for its anticancer chemotherapeutic and immunomodulatory benefits. Saracatinib is currently in clinical trials as a potential treatment for a variety of cancers, including non-small cell lung cancer (NSCLC), pancreatic cancer, gastric cancer, and myeloma. In cellular and animal models, this compound inhibits migration, invasion, and growth of cancer cells. Additionally, saracatinib displays mixed immunomodulatory effects, decreasing T cell cytokine production in one in vitro model and increasing CD8+ memory T cells and production of IFN-γ in another in vitro model.

Product Info

Cas No.

379231-04-6
Purity

≥98%
Formula

C27H32ClN5O5
Formula Wt.

542.03
Chemical Name

N-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methyl-1-piperazinyl)ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-4-quinazolinamine
IUPAC Name

N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(oxan-4-yloxy)quinazolin-4-amine
Synonym

AZD-0530
Appearance

Off white powder

Shipping and Storage

Store Temp

Ambient
Ship Temp

Ambient

Downloads

MSDS

S0168 MSDS PDF
Info Sheet

S0168 Info Sheet PDF

References

Gangadhar TC, Clark JI, Karrison T, et al. Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma. Invest New Drugs. 2013 Jun;31(3):769-73. PMID: 23151808.

Nam HJ, Im SA, Oh DY, et al. Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer. Mol Cancer Ther. 2013 Jan;12(1):16-26. PMID: 23144237.

Cavalloni G, Peraldo-Neia C, Sarotto I, et al. Antitumor activity of Src inhibitor saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas. Mol Cancer Ther. 2012 Jul;11(7):1528-38. PMID: 22452946.

Takai S, Sabzevari H, Farsaci B, et al. Distinct effects of saracatinib on memory CD8+ T cell differentiation. J Immunol. 2012 May 1;188(9):4323-33. PMID: 22450814.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • P3469

    Pirfenidone

    Collagen synthesis inhibitor.

    ≥98%
  • I0801

    IC261

    Casein kinase 1 inhibitor.

    ≥98%
  • C000082

    C-82

    beta-catenin inhibitor

    ≥99%
  • A5030

    4-Aminophenylphosphate Monosodium

    Alkaline phosphatase substrate used to quantify...

    ≥97%
  • O2145

    Ofloxacin Hydrochloride

    Fluoroquinolone; topoisomerase IV and bacterial...

    ≥98%
  • I7360

    Isosorbide Mononitrate

    NO donor.

    ≥98%
  • P2508

    Phenethyl Isothiocyanate

    ITC found in cruciferous vegetables.

    ≥99%
  • N7200

    NS-11394

    GABA-A α5/3/2 positive modulator.

    ≥98%
  • B1992

    Bexarotene

    RXR agonist.

    ≥98%
  • K3352

    Kinetensin

    Peptide, neurotensin analog.

    ≥95%
  • V7200

    VS-5584

    PI3K inhibitor.

    ≥98%
  • C022682

    2-Carbomethoxy-3-thiophenesulfonyl Chloride

    Building block

    ≥98%
  • C2900

    CH5424802

    ALK inhibitor.

    ≥99%
  • D3215

    Didymin

    Flavonoid glycoside found in citrus fruit.

    ≥98%
  • G1658

    Gentamycin Sulfate

    Aminoglycoside; protein translation inhibitor.<...
  • T1020

    n-Butyl Analog of Paclitaxel

    Fermentation impurity

    ≥95%
  • P0013

    P7C3

    Aminopropyl carbazole, neuroprotective.

    ≥98%
  • N7209

    NSC-207895

    Benzofuroxan derivative; MDMX inhibitor.

    ≥98%
  • P298576

    Phomopsin A

    Cyclic hexapeptide isolated from Phomopsis lept...

    ≥98%
  • T2970

    Thrombin Receptor Agonist Peptide

    Peptide; PAR1 agonist.

    ≥95%